Compare AbCellera Biologics Inc (ABCL) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs JetBlue Airways Corporation — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while JetBlue Airways Corporation trades at $5.61 (market cap $2.13B). The key difference: AbCellera Biologics Inc and JetBlue Airways Corporation are close in size by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| ABCL | JBLU | |
|---|---|---|
Market Cap | $2.35B | $2.13B |
Sector | Health | Industrials |
52-Week High | $8.12 | $6.46 |
52-Week Low | $2.78 | $4.03 |
Enterprise Value | $1.99B | $9.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
JetBlue (JBLU) trades at $5.72, down 4.98% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The airline faces fundamental challenges with negative net income margins (-7.78%) and ROE (-33.51%) despite a low P/S ratio of 0.24. Recent strategic shifts include expanding premium Mint service in Fort Lauderdale while reducing New York operations to cut costs.
The outlook remains cautious with Wall Street showing limited conviction (19% buy rating) and a consensus price target of $5.12 below current levels. Key risks include persistent losses, high debt levels (debt-to-asset ratio over 50%), and competitive pressures, though lower fuel costs and travel demand provide some sector support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
